Drug Discovery for Paediatric Chagas Disease

Title:Drug Discovery for Paediatric Chagas Disease

Volume: 18 Issue: 9

Author(s): Sreekanth Thota*Carlos M. Morel

Affiliation:

• National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Fundacao Oswaldo Cruz - Ministerio da Saude, Av. Brazil 4036 - Predio da Expansao, 8º Andar - Sala 814, Manguinhos, 21040-361 - Rio de Janeiro - RJ,Brazil

Keywords: Chagas disease, congenital, infants, symptoms, treatment, Trypanosoma cruzi.

Abstract: Chagas disease is caused by the parasite Trypanosoma cruzi and is regularly found among particular people living in Central and South America. Paediatric Chagas disease occurs in 1-10% of infants of infected mothers. The major important point considered in the treatment of congenital Chagas disease focuses on killing the parasite in acute infection and managing signs and symptoms in later stages. Nowadays, two drugs benznidazole and nifurtimox are currently available in the market for the treatment of paediatric Chagas disease.

Cite this article as:

Thota Sreekanth*, Morel M. Carlos, Drug Discovery for Paediatric Chagas Disease, Mini-Reviews in Medicinal Chemistry 2018; 18 (9) . https://dx.doi.org/10.2174/1389557516666161226155204